2023 World Conference on Lung Cancer (Posters)-P1.22. ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments

P1.22. ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference discussed the potential use of ERBB3 and BRAF mutations as biomarkers in non-small cell lung cancer (NSCLC) patients undergoing immunotherapy-based treatments. The researchers aimed to identify biomarkers that could predict patient outcomes and disease progression. Liquid biopsy samples were collected from 63 stage IV NSCLC patients before receiving treatment. Next-generation sequencing was used to analyze circulating-cell-free DNA (cfDNA) for genetic alterations. The study found that genetic alterations were detected in 80.95% of the liquid biopsy samples, with BRAF mutations being among the most prevalent. Patients with BRAF-mutated tumors did not experience disease progression or death while receiving immunotherapy or chemo-immunotherapy. On the other hand, alterations in the ERBB3 gene were associated with disease progression, with patients with ERBB3 mutated tumors experiencing earlier disease progression and worse overall survival compared to those without ERBB3 mutations. The study suggests that the presence of BRAF pathogenic variants may serve as a good prognostic factor in stage IV NSCLC patients undergoing immunotherapy or chemo-immunotherapy. Conversely, pathogenic mutations in ERBB3 could indicate a high risk of disease progression. The authors emphasize the need for further studies with larger patient cohorts to validate these findings. Overall, the study highlights the potential of genetic biomarkers in predicting patient outcomes and tailoring treatment strategies for NSCLC patients undergoing immunotherapy-based treatments.

Asset Subtitle

Lucía Robado de Lope

Meta Tag

Speaker Lucía Robado de Lope

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

ERBB3 mutations

BRAF mutations

biomarkers

non-small cell lung cancer

NSCLC

immunotherapy

liquid biopsy

circulating-cell-free DNA

disease progression

patient outcomes